BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38335717)

  • 1. Validation of the clinical performance and reproducibility of the NeuMoDx HPV assay self-sample workflow.
    Heideman DAM; Berkhof J; Verhoef L; Ouwerkerk C; Smit PW; Oštrbenk Valenčak A; Mlakar J; Poljak M; Steenbergen RDM; Bleeker MCG
    J Clin Virol; 2024 Apr; 171():105649. PubMed ID: 38335717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening.
    Heideman DAM; Oštrbenk Valenčak A; Doorn S; Bonde J; Hillemanns P; Gimpelj Domjanič G; Mlakar J; Hesselink AT; Meijer CJLM; Poljak M
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
    Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
    J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
    Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
    J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
    Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
    J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
    Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
    Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of BD Onclarity HPV assay on FLOQSwabs vaginal self-samples.
    Martinelli M; Latsuzbaia A; Bonde J; Pedersen H; Iacobone AD; Bottari F; Piana AF; Pietri R; Cocuzza CE; Arbyn M;
    Microbiol Spectr; 2024 Mar; 12(3):e0287223. PubMed ID: 38323823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples.
    Avian A; Clemente N; Mauro E; Isidoro E; Di Napoli M; Dudine S; Del Fabro A; Morini S; Perin T; Giudici F; Cammisuli T; Foschi N; Mocenigo M; Montrone M; Modena C; Polenghi M; Puzzi L; Tomaic V; Valenti G; Sola R; Zanolla S; Vogrig E; Riva E; Angeletti S; Ciccozzi M; Castriciano S; Pachetti M; Petti M; Centonze S; Gerin D; Banks L; Marini B; Canzonieri V; Sopracordevole F; Zanconati F; Ippodrino R
    J Transl Med; 2022 May; 20(1):231. PubMed ID: 35581584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.
    Polman NJ; Ebisch RMF; Heideman DAM; Melchers WJG; Bekkers RLM; Molijn AC; Meijer CJLM; Quint WGV; Snijders PJF; Massuger LFAG; van Kemenade FJ; Berkhof J
    Lancet Oncol; 2019 Feb; 20(2):229-238. PubMed ID: 30658933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Performance of the RealTi
    Latsuzbaia A; Vanden Broeck D; Van Keer S; Weyers S; Tjalma WAA; Doyen J; Donders G; De Sutter P; Vorsters A; Peeters E; Arbyn M
    Microbiol Spectr; 2022 Oct; 10(5):e0163122. PubMed ID: 36047900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
    Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
    J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
    Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
    BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
    Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
    BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
    Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
    BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN.
    Dijkstra MG; Heideman DA; van Kemenade FJ; Hogewoning KJ; Hesselink AT; Verkuijten MC; van Baal WM; Boer GM; Snijders PJ; Meijer CJ
    J Clin Virol; 2012 Jun; 54(2):147-51. PubMed ID: 22445557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population.
    Cuzick J; Cadman L; Ahmad AS; Ho L; Terry G; Kleeman M; Lyons D; Austin J; Stoler MH; Vibat CRT; Dockter J; Robbins D; Billings PR; Erlander MG
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1053-1059. PubMed ID: 28223432
    [No Abstract]   [Full Text] [Related]  

  • 19. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
    Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
    J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.